The Russian pharmaceutical concern R-Pharm will spend millions to expand its headquarters in the Bavarian town of Illertissen (Neu-Ulm district). According to the head of the plant, Ivan Semenov, in an interview with the daily “Südwest Presse”, the investment value exceeds EUR 20 million. As early as the first quarter of next year, production of the so-called Oxford vaccine against coronavirus.
Coronavirus vaccine in pivotal testing phase
The Russian parent company intends to adapt the factory to the requirements of sterile production. It is estimated that up to 500 million doses of the vaccine will be produced there annually. The medicine will go to 35 countries, including the Commonwealth of Independent States. However, it will not be intended for German and other members of the European Union. The Oxford vaccine (AZD1222) is currently in the third phase of testing, i.e. the conclusive one.
Watch the video
The universities are preparing for the new academic year. The coronavirus has created new fields for research
–
This future antidote to COVID-19, being developed by the British-Swedish concern AstraZeneca, has just entered USA in the advanced phase of clinical trials. Until phase III, nearly 30,000 are sought. volunteers to test AZD1222. Participants will be given two doses of either saline placebo or the vaccine four weeks apart.
As reported in July by AstraZeneca, research in the initial or middle stage showed that the drug is characterized by a “high tolerance tolerance and a strong immune response” to SARS-CoV-2, i.e. the virus causing COVID-19. According to the “Independent” daily, further tests are to be conducted in Brazil, South Africa and Russia, and their results should be known later this year.
3 billion vaccines a year
AstraZeneca has already signed production agreements with some countries, including Russia. The goal is to achieve an annual production of around 3 billion doses of the vaccine. Also a few weeks ago European Union agreed with the concern a contract for the supply of 400 doses.
It is possible that the plant in Illertissen, Bavaria, will also produce the Russian “Sputnik V” vaccine in the future. Although the substance remained in Russia approved for use, but tests have not shown compliance with international standards.
The article comes from the Deutsche Welle website
–
Related
